The maleimide groups terminated at the DSPE-PEG-Mal chain ends have also been decorated with anti-HER2 affibody by Feng et al., who synthesized CPNs based on PFVBT and PIDTTQ, and DSPE-PEG2K-Mal and achieved superior selectivity towards tumour cells with HER2 overexpression [71]. Here, ERBB2 is linked to neoplasm.